# COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY

> **NIH NIH N01** · MESO SCALE DIAGNOSTICS, LLC · 2020 · $1,499,726

## Abstract

The company is working to develop serology assays for CoV-2 vaccine studies.  
 The project leverages experience in developing and manufacturing high-throughput serology assays, and addresses the need for high quality CoV-2 reagents and tests that can be reproducibly manufactured at large scale.  They also propose a study – in collaboration with Kaiser Permanente - to evaluate measurement of antibodies in saliva to assess immunity to SARS-CoV-2.

## Key facts

- **NIH application ID:** 10260009
- **Project number:** 272201700013C-P00008-9999-2
- **Recipient organization:** MESO SCALE DIAGNOSTICS, LLC
- **Principal Investigator:** GEORGE SIGAL
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,499,726
- **Award type:** —
- **Project period:** 2017-03-15 → 2021-05-10

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260009

## Citation

> US National Institutes of Health, RePORTER application 10260009, COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY (272201700013C-P00008-9999-2). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10260009. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*